Navigation Links
Volcano Corporation Schedules First Quarter Conference Call, Webcast
Date:4/27/2009

SAN DIEGO, April 27 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, today announced that it will report its operating results for the first quarter of fiscal 2009 on Tuesday, May 5.

The company will hold a conference call to discuss its financial results and operating activities open to all interested parties at 2 p.m., Pacific Daylight Time (5 p.m., Eastern Daylight Time), Tuesday, May 5, hosted by Scott Huennekens, president and chief executive officer, and John Dahldorf, chief financial officer.

The teleconference can be accessed by calling (719) 325-4826, passcode 5095234. Please dial in 10-15 minutes prior to the beginning of the call. The webcast will be available through the company's website at www.volcanocorp.com.

A replay of the conference call will be available through Tuesday, May 12, at (719) 457-0820, passcode 5095234, and via the company's website.

About Volcano Corporation

Volcano Corporation (Nasdaq: VOLC) offers a broad suite of devices designed to facilitate endovascular procedures, enhance the diagnosis of vascular and structural heart disease and guide optimal therapies. The company's intravascular ultrasound (IVUS) product line includes ultrasound consoles that can be intergraded directly into virtually any modern cath lab. Volcano IVUS offers unique features, including both single-use phased array and rotational IVUS imaging catheters, and advanced functionality operations, such as VH(R) IVUS tissue characterization and ChromaFlo(R). Volcano also provides functional measurement (FM) consoles and single-use pressure and flow guide wires and is developing a line of ultra-high resolution Optical Coherence Tomography (OCT) systems and catheters. Currently, more than 4,000 Volcano IVUS and FM systems are installed worldwide, with approximately half of is revenues coming from outside the United States. For more information, visit the company's website at http://www.volcanocorp.com


'/>"/>
SOURCE Volcano Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Volcano Corporation Presentation at Bear Stearns Conference to be Webcast
2. Volcano Corporation Announces Pricing of Common Stock Offering
3. Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated
4. Volcano Announces Closing of CardioSpectra Acquisition
5. Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast
6. Volcano Announces FDA 510(k) Clearance of Revolution Rotational Catheter and FFR for the s5i Integrated IVUS Console
7. Volcano Corporation Presentation at Cowen Healthcare Conference to be Webcast
8. Volcano Announces U.S. and European Launch of Rotational IVUS and Integrated FFR
9. Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent
10. Volcano Corp Announces First Human Use of the Volcano Optical Coherence Tomography (OCT) Imaging Catheter
11. Volcano Announces Placement of 1,000th s5 and s5i IVUS Imaging System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... Interpace Diagnostics Group, Inc. (NASDAQ: IDXG)("Interpace" ... useful molecular diagnostic tests and pathology services, today ... purchase agreement with three  institutional investors to purchase ... in a registered direct offering.  In a concurrent ... to the same investors warrants to purchase 855,000 ...
(Date:1/21/2017)... Jan. 20, 2017 Aratana Therapeutics, Inc. (NASDAQ: ... on the licensing, development and commercialization of innovative biopharmaceutical ... Best Company in North America ... award based on the FDA approval of three ... ENTYCE ® (capromorelin oral solution) and NOCITA ® ...
(Date:1/20/2017)... , ... January 20, 2017 , ... The two newest ... treatment options for patients. Vironika, a spin out from The Wistar Institute, and Sanguis, ... lab space at 3624 Market Street. , Vironika is developing a treatment for ...
(Date:1/20/2017)... , Jan. 20, 2017 Ginkgo ... of Gen9, a pioneer in the synthesis and ... unique expertise in assembling pathway-length synthetic DNA into ... and capacity in the construction of new organism ... industries. "Gen9 was founded to significantly ...
Breaking Biology Technology:
(Date:1/11/2017)... , Jan. 11, 2017 Intoxalock, a leading ... the release of its patent-pending calibration device. With this ... perform calibrations, securely upload data logs and process repairs ... customer. "Fighting drunk driving through the application ... public at large, but also for the customer who ...
(Date:1/6/2017)... Jan. 6, 2017  Privately-held CalciMedica, Inc., announced ... healthy volunteers of a novel calcium release-activated calcium ... pancreatitis. Acute pancreatitis, sudden painful ... disorder, but can be very serious.  In severe cases ... where extended hospital stays, time in the ICU ...
(Date:1/6/2017)... 5, 2017  Delta ID Inc., a leader in ... for automotive at CES® 2017. Delta ID has collaborated ... demonstrate the use of iris scanning as a secure, ... driver in a car, and as a way to ... Delta ID and Gentex will demonstrate (booth ...
Breaking Biology News(10 mins):